Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Platelet-Rich Plasma as an Alternative to Xenogeneic Sera in Cell-Based Therapies: A Need for Standardization.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- المؤلفون: Anitua, Eduardo1,2,3 (AUTHOR) ; Zalduendo, Mar1,2 (AUTHOR) ; Troya, Maria1,2 (AUTHOR) ; Alkhraisat, Mohammad H.1,2 (AUTHOR); Blanco-Antona, Leticia Alejandra4 (AUTHOR)
- المصدر:
International Journal of Molecular Sciences. Jun2022, Vol. 23 Issue 12, p6552-6552. 28p.
- الموضوع:
- معلومة اضافية
- نبذة مختصرة :
There has been an explosion in scientific interest in using human-platelet-rich plasma (PRP) as a substitute of xenogeneic sera in cell-based therapies. However, there is a need to create standardization in this field. This systematic review is based on literature searches in PubMed and Web of Science databases until June 2021. Forty-one studies completed the selection criteria. The composition of PRP was completely reported in less than 30% of the studies. PRP has been used as PRP-derived supernatant or non-activated PRP. Two ranges could be identified for platelet concentration, the first between 0.14 × 106 and 0.80 × 106 platelets/µL and the second between 1.086 × 106 and 10 × 106 platelets/µL. Several studies have pooled PRP with a pool size varying from four to nine donors. The optimal dose for the PRP or PRP supernatant is 10%. PRP or PRP-derived supernatants a have positive effect on MSC colony number and size, cell proliferation, cell differentiation and genetic stability. The use of leukocyte-depleted PRP has been demonstrated to be a feasible alternative to xenogeneic sera. However, there is a need to improve the description of the PRP preparation methodology as well as its composition. Several items are identified and reported to create guidelines for future research. [ABSTRACT FROM AUTHOR]
No Comments.